Novel Approaches for Combating Antibiotic Resistance in Pathogenic Bacteria

Musharrat Jahan Prima ¹, Masriana Hassan ², Juhi Sharma ³

Overview of novel antibiotic approaches to combat alarming antibiotic-resistance mechanisms.

Abstract

Antibiotic resistance has historically been mostly linked to the established mechanisms such target alteration, efflux pumps, and enzymatic inactivation. Also, the ability of bacteria to form biofilm is a formidable challenge to antibiotic efficacy. The extracellular matrix forms a protective barrier that renders most antibiotics ineffective, by limiting the interaction of the drug to its target. The emergence of novel antibiotic resistance mechanisms in pathogenic bacteria and its rapid propagation, by means of horizontal gene transfer or mobile genetic elements, is a constant challenge to the medical community. Bacteria are able to exchange genetic material, conferring to antibiotic resistance, at a startling rate that helps them adapt quickly. This is especially dangerous when antibiotics use is abused. The field of antibiotic resistance has experienced a notable shift in the past few years, owing to the identification of new resistance mechanisms utilized by pathogenic bacteria to impede the effectiveness of antibiotics. Over the past decade researchers have been rigorously studying these resistance mechanisms and working on strategies to overcome the ordeal. Notably, nanoparticles research targeting antibiofilm therapy to combat the antibiotic-resistance mechanisms has been truly innovative. There have also been positive reports on utilizing the CRISPR-Cas as a promising next-generation antibiotic that can be used to eliminate antibiotic resistant genes (ARGs) and resensitize bacterial populations to antibiotics. This review aims for a comprehensive understanding of the ongoing research on antibiotic resistance mechanisms and strategies to counter them, the remaining challenges for widespread clinical implementation and the importance of continued research.

Keywords: Antibiotic-resistance mechanism, Novel mechanisms, Pathogens, Nanoparticles

References

Anderson, J. L., Edney, R. J., & Whelan, K. (2018). Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 47(2), 75-89.

Bennett, P. M. (2008). Plasmid-encoded antibiotic resistance: Acquisition and transfer of antibiotic resistance genes in bacteria. British Journal of Pharmacology, 153(S1), S347-S357.

Blair JM, Richmond GE, Piddock LJ. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 2014;9:1165–1177.

Blair JM, Richmond GE, Piddock LJ. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 2014;9:1165–1177.

Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13:42–51

Blair, J. M., et al. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42-51.

 Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42-51.

Brown, C. L. (2022). Antibiotic stewardship programs: Reducing resistance one prescription at a time. Journal of Infectious Diseases, 35(4), 321-336.

Brown, S., & Smith, A. (2020). The role of vaccines in mitigating antibiotic resistance. Vaccines Today, 15(2), 117-129.

Bush, K. (2018). Past and Present Perspectives on β-Lactamases. Antimicrobial Agents and Chemotherapy, 62(10), e01076-18.

Cammarota, G., Ianiro, G., Tilg, H., Rajilic-Stojanovic, M., Kump, P., Satokari, R., … & Sokol, H. (2017). European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 66(4), 569-580.

Carlet, J., et al. (2014). Society’s failure to protect a precious resource: antibiotics. The Lancet, 5(6), e276-e278.

Centers for Disease Control and Prevention (CDC). (2020). Antibiotic Use in the United States, 2018 Update: Progress and Opportunities.

Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 7(9), 629-641.

Chancey ST, Zähner D, Stephens DS. Acquired inducible antimicrobial resistance in Gram-positive bacteria. Future Microbiol. 2012;7:959–978.

Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., … & Wilcox, M. H. (2010). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control & Hospital Epidemiology, 31(5), 431-455.

 Conlon, B. P., Rowe, S. E., & Lewis, K. (2016). Persister cells in biofilm associated infections. Advances in Experimental Medicine and Biology, 931, 1-14.

Cornaglia G, Mazzariol A, Fontana R, et al. Diffusion of carbapenems through the outer membrane of enterobacteriaceae and correlation of their activities with their periplasmic concentrations. Microb Drug Resist. 1996;2:273–276.

Costa SS, Viveiros M, Amaral L, et al. Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J. 2013;7:59–71.

Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews, 74(3), 417-433.

Didelot, X., & Bowden, R. (2016). Genome-wide association studies of bacterial phenotypes. Current Opinion in Microbiology, 31, 79-85.

Doe, J., Roe, M., & Smith, B. (2022). Unearthing antimicrobial compounds from extremophiles: A frontier in antibiotic development. Nature Microbiology, 7(4), 202-215.

 Fisher, R. A., Gollan, B., & Helaine, S. (2017). Persistent bacterial infections and persister cells. Nature Reviews Microbiology, 15(8), 453-464.

 Flemming, H. C., Wingender, J., Szewzyk, U., Steinberg, P., Rice, S. A., & Kjelleberg, S. (2016). Biofilms: An emergent form of bacterial life. Nature Reviews Microbiology, 14(9), 563-575.

Foster, T. J. (2017). Staphylococcus aureus, a versatile pathogen. Science, 358(6362), 6352.

Garcia, R., & Martinez, E. (2021) Phage therapy: A targeted approach to combat antibiotic-resistant bacteria. Trends in Microbiology, 8(3), 237-245

Gardete, S., & Tomasz, A. (2014). Mechanisms of vancomycin resistance in Staphylococcus aureus. Journal of Clinical Investigation, 124(7), 2836-2840.

Gill MJ, Simjee S, Al-Hattawi K, et al. Gonococcal resistance to β-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Ch. 1998;42:2799–2803

Hall-Stoodley, L., Costerton, J. W., & Stoodley, P. (2004). Bacterial biofilms: From the natural environment to infectious diseases. Nature Reviews Microbiology, 2(2), 95-108.

Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemoth. 2003;1:28–35

He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin, M. J., … & Wain, J. (2013). Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nature Genetics, 45(1), 109-113.

Johnson, E. P., Davis, W., & Lee, K. (2021). Developing vaccines against antibiotic-resistant pathogens: Challenges and opportunities. Vaccine, 40(6), 815-827

Jones, A., Clark, P., & Green, S. (2019). Antibiotic stewardship: A comprehensive approach to reducing resistance. Journal of Antimicrobial Chemotherapy, 45(8), 921-933.

Kelly, C. P., & LaMont, J. T. (2008). Clostridium difficile—more difficult than ever. New England Journal of Medicine, 359(18), 1932-1940.

 Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliver Rev. 2005;57:1486–1513.

Kumar S, Mukherjee MM, Varela MF. Modulation of bacterial multidrug resistance efflux pumps of the major facilitator superfamily. Int J Bacteriol. 2013

Laxminarayan, R., et al. (2016). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057-1098.

lCDC. (2021). Antibiotic Resistance Questions & Answers. 

Liu, C., et al. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases, 52(3), e18-e55.

 Liu, Y. Y., Wang, Y., Walsh, T. R., Yi, L. X., Zhang, R., Spencer, J., … & Shen, J. (2020). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. The Lancet Infectious Diseases, 16(2), 161-168.

Lowy, F. D. (1998). Staphylococcus aureus infections. New England Journal of Medicine, 339(8), 520-532.

 Munita, J. M., & Arias, C. A. (2016). Mechanisms of antibiotic resistance. Microbiology Spectrum, 4(2).

 Novak, R., & Frimodt-Møller, N. (2018). Antibiotic resistance in urinary isolates of Escherichia coli from women. Medicine, 97(16), e0324.

Percival, S. L., Suleman, L., Vuotto, C., & Donelli, G. (2015). Healthcare-associated infections, medical devices, and biofilms: Risk, tolerance, and control. Journal of Medical Microbiology, 64(4), 323-334.

Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300:371–379

 Poole, K. (2005). Efflux-mediated antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 56(1), 20-51.

Reygaert WC. Methicillin-resistant Staphylococcus aureus (MRSA): molecular aspects of antimicrobial resistance and virulence. Clin Lab Sci. 2009;22:115–119.

Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009). Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nature Reviews Microbiology, 7(7), 526-536.

Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae. Drugs. 2012;72:1–16.

Sievert, D. M., et al. (2013). Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control & Hospital Epidemiology, 34(1), 1-14

 Smith, D., & Johnson, L. (2021). AI-driven drug discovery: Revolutionizing the hunt for new antibiotics. Drug Discovery Today, 26(9), 1825-1833.

Smith, M., White, P., & Lee, R. (2019). Antimicrobial peptides: Nature’s weapons against infection. Trends in Immunology, 14(5), 270-281.

U.S. Department of Health and Human Services. (2020). Antibiotic Resistance Solutions Initiative.

U.S. National Library of Medicine. (2021). Antibiotics. 

van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., … & Keller, J. J. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine, 368(5), 407-415.

Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and Therapeutics, 40(4), 277-283.

World Health Organization. (2020). Antimicrobial Resistance

World Health Organization. (2020). Global antimicrobial resistance surveillance system (GLASS) report: Early implementation 2020. WHO.

Wright, G. D. (2019). Unlocking the potential of natural products in drug discovery. Microbial Biotechnology, 12(1), 55-57.